AZITAR-500 Tablet

Treatment of infections caused by sensitive organisms.

Lower Respiratory Tract Infections: Community - acquired pneumonias, acute bacterial exacerbations of chronic obstructive pulmonary disease, acute bronchitis due to Haemophilus influenzae, Moraxella catarrhalis or Streptococcus pneumoniae.

Upper Respiratory Tract Infections: Ear, nose and throat infections e.g. tonsillitis, sinusitis, otitis media and pharyngitis.

Skin/Skin Structure Infections: Furunculosis, pyoderma and impetigo due to Staphylococcus aureus, S.pyogenes or S.agalactiae.

Sexually Transmitted Disease: Due to N.gonorrhoae and C.trachmatis.

Dosage

Mild to moderate Bacterial Exacerbations of Chronic Obstructive Pulmonary Disease, Pneumonia, Pharyngitis / Tonsillitis and Uncomplicated Skin and Skin Structure Infections (>15 years of age): 500mg as a single dose on the 1st day followed by 250mg once daily on days 2 through 5 for a total dose of 1.5g or 500mg once daily for 3 days.

Sexually Transmitted Diseases including Urethritis & Cervicitis due to C.trachomatis and N.Gonotthoeae: Single dose of 1g.

Administer at least 1 hr before or 2 hrs after a meal. Azithromycin should not be taken with food.

Hypersensitivity to azithromycin, erythromycin or any macrolide antibiotic.

Most adverse effects are mild to moderate in severity and are reversible upon discontinuation of azithromycin. Overall, the most common adverse effect in patients receiving the multiple - dose regimen was related to the gastrointestinal system with diarrhoea (5), nausea and abdominal pain (3%) being the most frequently reported. The following adverse reaction occurred in <1% of patients:

Cardiovascular: Palpitations and chest pain.

Gastrointestinal: Dyspepsia, flatulence, vomiting, melena and cholestatic jaundice.

Genitourinary: Moniliasis, vaginitis and nephritis.

Central Nervous System: Dizziness, vertigo, somnolence and fatigue.

Allergic: Rash, photosensitivity and angioedema.

Aluminium and magnesium containing antacids reduce the peak serum levels but not the extent of azithromycin absorption. Therefore, patients should be cautioned not to take the aluminium and magnesium containing antacids and azithromycin simultaneously.

Theophylline: Azithromycin did not affect the plasma levels or pharmacokinetics of theophylline administered as a single I.V. dose. However, concurrent use of macrolides and theophylline has been associated with increases in serum concentrations of theophylline.

Therefore, until further data is available, plasma theophylline levels must be carefully monitored in patients receiving azithromycin concomitantly.

Warfarin: Azithromycin does not affect the prothrombin time response to a single dose of warfarin. However, concurred use of macrolides and warfarin has been associated with increased anticoagulant effects. Prothrombin time should be carefully monitored in all patients being treated with azithromycin and warfarin concomitantly.

Use in lactation: It is not known whether azithromycin is excreted in breast milk. Exercise caution when administering to a nursing woman.

Hepatic/Renal function impairment: Because azithromycin is principally eliminated via the liver, caution should be exercised when administered to patients with impaired hepatic function. There is no date regarding azithromycin usage in patients with renal impairment, however, caution should be exercised when prescribing azithromycin to these patients.

Use in the elderly: Pharmacokinetic parameters in older volunteers (65-85 years) were similar to those in younger volunteers (18-40 years) for the 5 day therapeutic regimen. Dosage adjustment does not appear to be necessary for older patients with normal renal and hepatic function receiving treatment with this dosage regimen.

The basic mechanism of action of azithromycin is inhibition of protein synthesis in the bacterial cell. Azithromycin binds reversibly to the 50S ribosomal subunit. This inhibits translocation of aminoacyl transfer - RNA and consequent protein synthesis.